Exegiline
MT-031 is a multifunctional drug designed for the treatment of dementia and Alzheimer Disease. Its structure combines Rivastigmine (Exelon) and Rasagiline (Azilect) moieties. It works as a dual Acetylcholinesterase (AChE) and Butyrylcholinesterase (BuChE) inhibitor as well a selective irreversible inhibition of MAO-A
Our findings demonstrated that MT-031 has the following attributes:
Intellectual Property
The molecule, its derivatives and applications are protected by the US and European recently granted patent.
ResQ Medical
Controlling The Bleeding In Time
ResQ Medical is developing ALMA, a unique and innovative solution for treating Postpartum Hemorrhage (PPH) which is a life-threatening condition.
ALMA is attentive to the natural physiological mechanism of the uterus to deal with PPH.
Our approach with ALMA is to support the natural contraction of the uterus which in turn leads to the cessation of the bleeding as occurring naturally in any normal birth, and which doesn’t occur in the case of PPH. This innovative approach contrasts with the medical devices used today, which are based on inserting and inflating a balloon inside the uterine cavity- causing the uterus to expend against the natural mechanism of the body.
Endopump
The new generation of therapy for Parkinson .
EndoPump is developing a new method of treatment to help in the management of Parkinson disease using an implanted continuous delivering system to deliver Levodopa by a unique formulation, achieving stable blood concentrations for 24/7 avoiding unnecessary side effects
The unique technology is implanted, and filled once in a week.
Dose controlled by the EndoPump Application by physician and patient.
achieving stable blood concentrations for 24/7 in any conditions.
internal, discreet, reduced risk of infection and comfortable for the Parkinson patient.
Mitralheal
MitralHeal Ltd. A novel catheter based technology replacement valve to replace a defective mitral valve for treating mitral regurgitation. Mitralheal’s System will allow physicians to offer therapy to patients who suffer from mitral regurgitation, and who currently have no good and safe solution/intervention for their condition. Mitralheal’s solution has the ability to provide patients with a new method to treat mitral valve diseases other than surgery-based or repair-only options, by a minimally invasive procedure. Thus, providing clinical benefit over mitral valve replacement surgery, with lower risks associated with minimally invasive approach.
Founded in 2012 by Youdim Pharmaceuticals with IP from Sheba Medical Center, the largest hospital in Israel and recognized among the top 10 in the world by Newsweek in 2019, 2020, 2021, and a teaching hospital of Tel Aviv University.